Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study

Anna Jansana, Isabel Del Cura, Alexandra Prados-Torres, Teresa Sanz Cuesta, Beatriz Poblador-Plou, A Gimeno Miguel, Manuela Lanzuela, Berta Ibañez, Ibai Tamayo, Conchi Moreno-Iribas, María Padilla-Ruiz, Maximino Redondo, Mercè Comas, Laia Domingo, Antonio Díaz-Holgado, Francisco Javier Salamanca, Xavier Castells, Maria Sala, SURBCAN group, Mercè Abizanda, Talita Duarte, Javier Louro, María Del Carmen Martínez, Cristóbal Molina, Guillermo Pérez, Ana María Muñoz, Óscar Toldos, Javier Baquedano, Rossana Burgui, Javier Gorricho, Anna Jansana, Isabel Del Cura, Alexandra Prados-Torres, Teresa Sanz Cuesta, Beatriz Poblador-Plou, A Gimeno Miguel, Manuela Lanzuela, Berta Ibañez, Ibai Tamayo, Conchi Moreno-Iribas, María Padilla-Ruiz, Maximino Redondo, Mercè Comas, Laia Domingo, Antonio Díaz-Holgado, Francisco Javier Salamanca, Xavier Castells, Maria Sala, SURBCAN group, Mercè Abizanda, Talita Duarte, Javier Louro, María Del Carmen Martínez, Cristóbal Molina, Guillermo Pérez, Ana María Muñoz, Óscar Toldos, Javier Baquedano, Rossana Burgui, Javier Gorricho

Abstract

Introduction: Breast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors.

Methods and analysis: Population-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018.

Ethics and dissemination: This study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations.

Trial registration number: This protocol is registered in Clinical Trials.gov (identifier: NCT03846999).

Keywords: breast tumours; epidemiology; primary care; public health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flowchart of the SURBCAN study. BCS, breast cancer survivor; SNS, Sistema nacional de salud (National Health Service); EMR, electronic medical record.
Figure 2
Figure 2
Variables included in the SURBCAN study.

References

    1. Cardoso F, Harbeck N, Barrios CH, et al. . Research needs in breast cancer. Ann Oncol 2017;28:208–17. 10.1093/annonc/mdw571
    1. Boyle P, Levin B. World cancer report 2008. Geneva: International Agency for Research on Cancer (IARC), 2010.
    1. Erikson C, Salsberg E, Forte G, et al. . Future simply and demand for oncologist: challenges to assuring access to oncology services. J OncolPract 2007;3:79–86.
    1. Noone A, Howlader N, Krapcho M, et al. . SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute, 2015.
    1. Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. 10.3322/caac.21492
    1. SEERStat Surveillance, epidemiology, and end results (seer) program. SEERStat database: Incidence-SEER-9 regulations. National cancer Institute, division of cancer control and population sciences, 2003. Available: [Accessed 20 Jul 2018].
    1. Baeyens-Fernández JA, Molina-Portillo E, Pollán M, et al. . Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study. BMC Cancer 2018;18:781. 10.1186/s12885-018-4682-1
    1. Engholm G, Ferlay J, Christensen N, et al. . NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010;49:725–36. 10.3109/02841861003782017
    1. Miller KD, Siegel RL, Lin CC, et al. . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271–89. 10.3322/caac.21349
    1. National Cancer Institute Public health research and cancer. Available: [Accessed 25 Jan 2019].
    1. Runowicz CD, Leach CR, Henry NL, et al. . American cancer Society/American Society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin 2016;66:43–73. 10.3322/caac.21319
    1. Alba E, Cruz J, Barón F, et al. . Monográfico SEOM de largos supervivientes en cáncer. Sociedad Española de Oncología Médica, 2012. Available:
    1. Hewitt M, Greenfield S, Stovall E. Delivering cancer survivorship care – from cancer patient to cancer survivor: lost in transition. TheNationalAcademiesPress. Washington DC 2006:187–321.
    1. Ewertz M, Land LH, Dalton SO, et al. . Influence of specific comorbidities on survival after early-stage breast cancer. Acta Oncol 2018;57:129–34. 10.1080/0284186X.2017.1407496
    1. Jordan JH, Thwin SS, Lash TL, et al. . Incident comorbidities and all-cause mortality among 5-year survivors of stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat 2014;146:401–9. 10.1007/s10549-014-3021-8
    1. Snyder CF, Frick KD, Herbert RJ, et al. . Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol 2013;31:1140–8. 10.1200/JCO.2012.43.0272
    1. Edwards MJ, Campbell ID, Lawrenson RA, et al. . Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2017;165:17–39. 10.1007/s10549-017-4295-4
    1. Parés-Badell O, Banqué M, Macià F, et al. . Impact of comorbidity on survival by tumour location: breast, colorectal and lung cancer (2000-2014). Cancer Epidemiol 2017;49:66–74. 10.1016/j.canep.2017.05.010
    1. Leach CR, Weaver KE, Aziz NM, et al. . The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv 2015;9:239–51. 10.1007/s11764-014-0403-1
    1. Mandelblatt JS, Lawrence WF, Cullen J, et al. . Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment. J Clin Oncol 2006;24:77–84. 10.1200/JCO.2005.02.2681
    1. Ong WL, Schouwenburg MG, van Bommel ACM, et al. . A standard set of value-based patient-centered outcomes for breast cancer: the International Consortium for health outcomes measurement (ICHOM) initiative. JAMA Oncol 2017;3:677–85. 10.1001/jamaoncol.2016.4851
    1. Bradshaw PT, Stevens J, Khankari N, et al. . Cardiovascular disease mortality among breast cancer survivors. Epidemiology 2016;27:6–13. 10.1097/EDE.0000000000000394
    1. Syrowatka A, Motulsky A, Kurteva S, et al. . Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat 2017;165:229–45. 10.1007/s10549-017-4290-9
    1. Nelson SH, Marinac CR, Patterson RE, et al. . Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors. Breast Cancer Res Treat 2016;155:551–7. 10.1007/s10549-016-3694-2
    1. Leysen L, Beckwée D, Nijs J, et al. . Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer 2017;25:3607–43. 10.1007/s00520-017-3824-3
    1. Jansana A, Posso M, Guerrero I, et al. . Health care services use among long-term breast cancer survivors: a systematic review. J Cancer Surviv 2019;13:477–93. 10.1007/s11764-019-00755-z
    1. Patnaik JL, Byers T, Diguiseppi C, et al. . The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011;103:1101–11. 10.1093/jnci/djr188
    1. Schneble EJ, Graham LJ, Shupe MP, et al. . Current approaches and challenges in early detection of breast cancer recurrence. J Cancer 2014;5:281–90. 10.7150/jca.8016
    1. Khatcheressian JL, Hurley P, Bantug E, et al. . Breast cancer follow-up and management after primary treatment: American Society of clinical oncology clinical practice guideline update. J Clin Oncol 2013;31:961–5. 10.1200/JCO.2012.45.9859
    1. Yeom YK, Chae EY, Kim HH, et al. . Screening mammography for second breast cancers in women with history of early-stage breast cancer: factors and causes associated with non-detection. BMC Med Imaging 2019;19:2. 10.1186/s12880-018-0303-3
    1. Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public health research. Annu Rev Public Health 2011;32:91–108. 10.1146/annurev-publhealth-031210-100700
    1. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. . Cohort profile: the epidemiology of chronic diseases and multimorbidity. The EpiChron cohort study. Int J Epidemiol 2018;47:382–4. 10.1093/ije/dyx259
    1. McBride ML, Groome PA, Decker K, et al. . Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study. BMC Cancer 2019;19:659. 10.1186/s12885-019-5882-z
    1. Grandjean I, Kwast ABG, de Vries H, KwastAB deVH, Klaase J, et al. . Evaluation of the adherence to follow-up care guidelines for women with breast cancer. Eur J Oncol Nurs 2012;16:281–5. 10.1016/j.ejon.2011.07.004
    1. REDISSEC Red de Investigación en servicios de salud en Enfermedades crónicas, 2013. Available: [Accessed 20 Jul 2019].
    1. Benchimol EI, Smeeth L, Guttmann A, et al. . The reporting of studies conducted using observational Routinely-collected health data (record) statement. PLoS Med 2015;12:e1001885. 10.1371/journal.pmed.1001885
    1. Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W–194. 10.7326/0003-4819-147-8-200710160-00010-w1
    1. Quan H, Sundararajan V, Halfon P, et al. . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–9. 10.1097/01.mlr.0000182534.19832.83
    1. Salisbury C, Johnson L, Purdy S, et al. . Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011;61:e12–21. 10.3399/bjgp11X548929
    1. MSSSI Base de datos clínicos de atención primaria del sistema nacional de salud-BDCAP, 2014. Available: [Accessed 10 Jul 2019].
    1. Birkhead GS. Successes and continued challenges of electronic health records for chronic disease surveillance. Am J Public Health 2017;107:1365–7. 10.2105/AJPH.2017.303938
    1. Kiasuwa Mbengi RL, Nicolaie AM, Goetghebeur E, et al. . Assessing factors associated with long-term work disability after cancer in Belgium: a population-based cohort study using competing risks analysis with a 7-year follow-up. BMJ Open 2018;8:e014094. 10.1136/bmjopen-2016-014094

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться